vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Zeta Global Holdings Corp. (ZETA). Click either name above to swap in a different company.
Zeta Global Holdings Corp. is the larger business by last-quarter revenue ($394.6M vs $281.3M, roughly 1.4× Guardant Health, Inc.). Zeta Global Holdings Corp. runs the higher net margin — 1.7% vs -45.7%, a 47.3% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 25.4%). Zeta Global Holdings Corp. produced more free cash flow last quarter ($60.9M vs $-54.2M). Over the past eight quarters, Zeta Global Holdings Corp.'s revenue compounded faster (42.3% CAGR vs 29.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Zeta Global Holdings Corp. is an American marketing technology company which was founded in 2007. Zeta offers companies a suite of multichannel marketing tools focused on creating, maintaining, and monetizing customer relationships. The company went public on the New York Stock Exchange on June 10, 2021, at a US$1.7 billion valuation.
GH vs ZETA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $394.6M |
| Net Profit | $-128.5M | $6.5M |
| Gross Margin | 64.6% | 59.5% |
| Operating Margin | -43.0% | 4.5% |
| Net Margin | -45.7% | 1.7% |
| Revenue YoY | 39.4% | 25.4% |
| Net Profit YoY | -15.8% | -57.1% |
| EPS (diluted) | $-1.01 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $394.6M | ||
| Q3 25 | $265.2M | $337.2M | ||
| Q2 25 | $232.1M | $308.4M | ||
| Q1 25 | $203.5M | $264.4M | ||
| Q4 24 | $201.8M | $314.7M | ||
| Q3 24 | $191.5M | $268.3M | ||
| Q2 24 | $177.2M | $227.8M | ||
| Q1 24 | $168.5M | $194.9M |
| Q4 25 | $-128.5M | $6.5M | ||
| Q3 25 | $-92.7M | $-3.6M | ||
| Q2 25 | $-99.9M | $-12.8M | ||
| Q1 25 | $-95.2M | $-21.6M | ||
| Q4 24 | $-111.0M | $15.2M | ||
| Q3 24 | $-107.8M | $-17.4M | ||
| Q2 24 | $-102.6M | $-28.1M | ||
| Q1 24 | $-115.0M | $-39.6M |
| Q4 25 | 64.6% | 59.5% | ||
| Q3 25 | 64.7% | 60.5% | ||
| Q2 25 | 65.0% | 62.1% | ||
| Q1 25 | 63.3% | 60.9% | ||
| Q4 24 | 61.6% | 60.0% | ||
| Q3 24 | 61.1% | 60.6% | ||
| Q2 24 | 59.1% | 60.0% | ||
| Q1 24 | 61.2% | 60.6% |
| Q4 25 | -43.0% | 4.5% | ||
| Q3 25 | -37.3% | 2.6% | ||
| Q2 25 | -45.9% | -1.7% | ||
| Q1 25 | -54.6% | -6.1% | ||
| Q4 24 | -62.4% | 2.2% | ||
| Q3 24 | -61.3% | -4.6% | ||
| Q2 24 | -56.8% | -11.7% | ||
| Q1 24 | -59.2% | -18.4% |
| Q4 25 | -45.7% | 1.7% | ||
| Q3 25 | -35.0% | -1.1% | ||
| Q2 25 | -43.0% | -4.2% | ||
| Q1 25 | -46.8% | -8.2% | ||
| Q4 24 | -55.0% | 4.8% | ||
| Q3 24 | -56.3% | -6.5% | ||
| Q2 24 | -57.9% | -12.3% | ||
| Q1 24 | -68.2% | -20.3% |
| Q4 25 | $-1.01 | $0.04 | ||
| Q3 25 | $-0.74 | $-0.02 | ||
| Q2 25 | $-0.80 | $-0.06 | ||
| Q1 25 | $-0.77 | $-0.10 | ||
| Q4 24 | $-0.90 | $0.10 | ||
| Q3 24 | $-0.88 | $-0.09 | ||
| Q2 24 | $-0.84 | $-0.16 | ||
| Q1 24 | $-0.94 | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $319.8M |
| Total DebtLower is stronger | $1.5B | $197.1M |
| Stockholders' EquityBook value | $-99.3M | $804.6M |
| Total Assets | $2.0B | $1.5B |
| Debt / EquityLower = less leverage | — | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $319.8M | ||
| Q3 25 | $580.0M | $385.2M | ||
| Q2 25 | $629.1M | $365.3M | ||
| Q1 25 | $698.6M | $364.4M | ||
| Q4 24 | $525.5M | $366.2M | ||
| Q3 24 | $585.0M | $418.5M | ||
| Q2 24 | $933.7M | $154.7M | ||
| Q1 24 | $1.0B | $141.6M |
| Q4 25 | $1.5B | $197.1M | ||
| Q3 25 | $1.1B | $196.9M | ||
| Q2 25 | $1.1B | $196.7M | ||
| Q1 25 | $1.1B | $196.5M | ||
| Q4 24 | $1.1B | $196.3M | ||
| Q3 24 | — | $196.1M | ||
| Q2 24 | — | $184.4M | ||
| Q1 24 | — | $184.2M |
| Q4 25 | $-99.3M | $804.6M | ||
| Q3 25 | $-354.5M | $689.2M | ||
| Q2 25 | $-305.5M | $673.3M | ||
| Q1 25 | $-250.8M | $676.6M | ||
| Q4 24 | $-139.6M | $676.8M | ||
| Q3 24 | $-60.1M | $474.9M | ||
| Q2 24 | $-1.6M | $217.0M | ||
| Q1 24 | $68.3M | $191.6M |
| Q4 25 | $2.0B | $1.5B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.3B | $1.1B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.5B | $1.1B | ||
| Q3 24 | $1.5B | $869.1M | ||
| Q2 24 | $1.6B | $583.9M | ||
| Q1 24 | $1.7B | $550.3M |
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.29× | ||
| Q3 24 | — | 0.41× | ||
| Q2 24 | — | 0.85× | ||
| Q1 24 | — | 0.96× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $64.1M |
| Free Cash FlowOCF − Capex | $-54.2M | $60.9M |
| FCF MarginFCF / Revenue | -19.3% | 15.4% |
| Capex IntensityCapex / Revenue | 9.9% | 0.8% |
| Cash ConversionOCF / Net Profit | — | 9.81× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $185.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $64.1M | ||
| Q3 25 | $-35.4M | $57.9M | ||
| Q2 25 | $-60.3M | $42.0M | ||
| Q1 25 | $-62.7M | $34.8M | ||
| Q4 24 | $-64.5M | $43.7M | ||
| Q3 24 | $-51.1M | $34.4M | ||
| Q2 24 | $-94.0M | $31.1M | ||
| Q1 24 | $-30.3M | $24.7M |
| Q4 25 | $-54.2M | $60.9M | ||
| Q3 25 | $-45.8M | $52.4M | ||
| Q2 25 | $-65.9M | $39.7M | ||
| Q1 25 | $-67.1M | $32.1M | ||
| Q4 24 | $-83.4M | $35.4M | ||
| Q3 24 | $-55.3M | $29.5M | ||
| Q2 24 | $-99.1M | $24.4M | ||
| Q1 24 | $-37.2M | $18.9M |
| Q4 25 | -19.3% | 15.4% | ||
| Q3 25 | -17.3% | 15.6% | ||
| Q2 25 | -28.4% | 12.9% | ||
| Q1 25 | -33.0% | 12.1% | ||
| Q4 24 | -41.3% | 11.3% | ||
| Q3 24 | -28.9% | 11.0% | ||
| Q2 24 | -55.9% | 10.7% | ||
| Q1 24 | -22.1% | 9.7% |
| Q4 25 | 9.9% | 0.8% | ||
| Q3 25 | 3.9% | 1.6% | ||
| Q2 25 | 2.4% | 0.8% | ||
| Q1 25 | 2.2% | 1.0% | ||
| Q4 24 | 9.4% | 2.6% | ||
| Q3 24 | 2.2% | 1.8% | ||
| Q2 24 | 2.9% | 3.0% | ||
| Q1 24 | 4.1% | 3.0% |
| Q4 25 | — | 9.81× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.87× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
ZETA
Segment breakdown not available.
